Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti–PD-1 therapy
Jielin Liu(Heilongjiang Academy of Sciences), Padmanee Sharma(The University of Texas MD Anderson Cancer Center)
Cited by 1
Related Papers
The Next Decade of Immune Checkpoint Therapy
|Cancer Discovery|2021|739
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
|Cancer Discovery|2018|570
CD8 tumor-infiltrating lymphocytes are predictive of survival in muscle-invasive urothelial carcinoma
|Proceedings of the National Academy of Sciences|2007|517
Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity
|Cancer Cell|2022|338